Infections in solid-organ transplantation: Difference between revisions
From IDWiki
m (Aidan moved page Solid-organ transplant infections to Infections in solid-organ transplantation) |
(linkified) |
||
Line 1: | Line 1: | ||
== |
==Pretransplant Screening== |
||
=== |
===Donor screen=== |
||
* |
*Bacterial: [[syphilis]], urine and blood cultures, bronchoalveolar lavage |
||
* |
*Viral: [[CMV after solid organ transplantation|CMV]], [[EBV]], [[HIV]], [[HBV]], [[HCV]], [[HSV]], [[VZV]], [[HTLV-1]] |
||
* |
*Other: [[Strongyloides stercoralis]], [[Chagas disease]] (sometimes) |
||
=== |
===Recipient Screen=== |
||
* |
*[[Prednisone]]: [[TB]]/[[HBV]]/[[Strongyloides]] |
||
* |
*[[Fludarabine]]: |
||
** |
**Lasts 6-12 months after last dose |
||
** |
**Listeria, PCP, and Nocardia |
||
* |
*[[Rituximab]]: as well as B-cell, can allow [[HBV]] and [[PJP]] infections |
||
* |
*[[Adalimumab]]: T-cell deficiency for months after last dose |
||
* |
*[[TNF-α inhibitors]]: similar to [[prednisone]] |
||
== |
==Post-Transplant Infections== |
||
=== |
===Early Infections (≤30 days)=== |
||
* T-cell deficit |
*Major risk factor is T-cell deficit, more than than B-cell deficit |
||
⚫ | |||
⚫ | |||
⚫ | |||
*Organ-specific |
|||
**Cardiac |
|||
⚫ | |||
⚫ | |||
**Lungs |
|||
***Donor-derived [[Ventilator-associated pneumonia|VAP]] |
|||
***Anastomotic infection, including fungal |
|||
**Liver: anastamotic leak, including [[VRE]] peritonitis |
|||
*Hospital-acquired: [[Central line-associated bloodstream infection|central line infections]] and resistant organisms |
|||
*Donor-derived bacterial infections, including [[syphilis]] |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
* Donor-derived VAP |
|||
* Anastomotic infection, including fungal Liver: anastamotic leak, including VRE peritonitis Hospital-acquired: central line infections and resistant organisms Donor-derived bacterial infections, including syphilis |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
**[[EBV]]/[[CMV after solid organ transplantation|CMV]]/[[HSV]]/[[VZV]] |
|||
**[[TB]], [[PCP]], [[Invasive fungal infection|invasive fungal infections]] |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
* EBV/CMV/HSV/VZV |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
[[Category:Transplant patients]] |
[[Category:Transplant patients]] |
Latest revision as of 21:38, 6 August 2020
Pretransplant Screening
Donor screen
- Bacterial: syphilis, urine and blood cultures, bronchoalveolar lavage
- Viral: CMV, EBV, HIV, HBV, HCV, HSV, VZV, HTLV-1
- Other: Strongyloides stercoralis, Chagas disease (sometimes)
Recipient Screen
- Prednisone: TB/HBV/Strongyloides
- Fludarabine:
- Lasts 6-12 months after last dose
- Listeria, PCP, and Nocardia
- Rituximab: as well as B-cell, can allow HBV and PJP infections
- Adalimumab: T-cell deficiency for months after last dose
- TNF-α inhibitors: similar to prednisone
Post-Transplant Infections
Early Infections (≤30 days)
- Major risk factor is T-cell deficit, more than than B-cell deficit
- Surgical site infection
- Bacterial
- Fungal: Aspergillus and Mucorales
- Organ-specific
- Cardiac
- LVAD infection
- Mycobacterial infection (very late)
- Lungs
- Donor-derived VAP
- Anastomotic infection, including fungal
- Liver: anastamotic leak, including VRE peritonitis
- Cardiac
- Hospital-acquired: central line infections and resistant organisms
- Donor-derived bacterial infections, including syphilis
Late Infections (30 days to 3-6 months)
- Major risk factor is T-cell deficit, more than B-cell deficit
- Occur as your withdraw prophylactic antimicrobials
- Reactivation infections
Very Late Infections (>6 months)
- B-cell deficits and variable T-cell deficits
- Usually regular community-acquired infections, but more severe